Abridge Extends AI Clinical Decision Support to Every Clinician in Partner Health Systems

Abridge has expanded its AI-powered clinical decision support capabilities to every clinician across participating partner health systems, marking a significant step in the company’s evolution from an AI documentation provider to a broader enterprise clinical intelligence platform. The expansion allows health systems to deploy Abridge’s clinical intelligence agent organisation-wide, including for clinicians who do not currently use its ambient AI documentation tools.

Since the expansion of its clinical decision support offering in April 2026, more than 300 enterprise health systems have adopted the solution. Abridge said monthly active users now exceed 50% of eligible clinicians, while the average number of queries per clinician has tripled over the past two months – indicating growing adoption of AI-enabled decision support within clinical workflows.

The partner organisations include major US health systems such as Kaiser Permanente, Sutter Health, UNC Health, CHRISTUS Health, Duke Health, and UPMC. Collectively, Abridge’s network of more than 300 enterprise health systems serves over 250 million patients, giving the expansion significant scale across the US healthcare ecosystem.

Seamless Integration Through Existing EHR Workflows

A key feature of the rollout is that the AI clinical intelligence agent can be deployed through the existing electronic health record (EHR) workflow already used by clinicians. Healthcare organisations can also provide access through dedicated mobile and web interfaces, connected to the patient chart. For clinicians already using Abridge as an AI scribe, the decision-support capabilities are integrated directly into their existing workflow.

Evidence-Based Insights Backed by Trusted Clinical Sources

The platform is designed to provide patient-contextual and evidence-based clinical insights, drawing on information relevant to the individual patient — including elements such as clinical history, medications, and other available data. Abridge has also expanded its evidence base through partnerships with Wolters Kluwer’s UpToDate, NEJM Group, and the American Medical Association’s JAMA Network, enabling clinicians to access peer-reviewed and trusted clinical information within the flow of care.

Supporting the Full Patient Encounter Journey

Abridge’s broader platform supports clinicians across different stages of the patient encounter – from preparing before a consultation and capturing clinical conversations, to generating structured documentation and surfacing relevant evidence-based information. The company has positioned this approach as part of a wider effort to reduce workflow fragmentation and make AI assistance available at the point of clinical decision-making.

Enterprise-Wide Deployment Within Existing Governance Structures

The expansion also allows health systems to deploy the technology through their existing security, governance, and EHR infrastructure, rather than requiring individual clinicians to adopt separate AI tools. This enterprise-wide approach could help healthcare organisations maintain greater oversight over how AI is used in clinical settings while reducing reliance on unapproved or disconnected tools.

A Broader Shift Toward Context-Aware Clinical Intelligence

With AI increasingly moving beyond clinical documentation into decision support, Abridge’s latest expansion reflects a broader shift toward context-aware clinical intelligence that combines patient information, clinical workflows, and evidence-based resources. By extending the technology to all clinicians within partner organisations, the company is aiming to make AI-assisted support a more integrated part of everyday healthcare delivery.